Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Update

Estrella Immunopharma, Inc. (NASDAQ:ESLA) saw a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 4,900 shares, a decline of 88.1% from the February 29th total of 41,100 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average daily volume of 45,400 shares, the short-interest ratio is presently 0.1 days.

Hedge Funds Weigh In On Estrella Immunopharma

An institutional investor recently bought a new position in Estrella Immunopharma stock. ATW Spac Management LLC acquired a new position in shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 40,000 shares of the company’s stock, valued at approximately $44,000. ATW Spac Management LLC owned 0.11% of Estrella Immunopharma at the end of the most recent reporting period. 0.35% of the stock is currently owned by institutional investors.

Estrella Immunopharma Stock Performance

Shares of ESLA stock traded down $0.01 during trading on Friday, reaching $1.24. The company’s stock had a trading volume of 20,903 shares, compared to its average volume of 58,715. The company has a 50-day simple moving average of $1.13. Estrella Immunopharma has a 1-year low of $0.86 and a 1-year high of $33.00.

Estrella Immunopharma (NASDAQ:ESLA) last issued its quarterly earnings data on Wednesday, February 14th. The company reported ($0.03) earnings per share for the quarter.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.